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Abstract 28 
Background: The burden of community-acquired pneumonia (CAP) caused by 29 
Streptococcus pneumoniae (pneumococcus) among adults in Europe is poorly defined. 30 
Methods: Structured searches of PubMed were conducted to identify the incidence of 31 
pneumococcal CAP among adults across Europe. 32 
Results: The overall incidence rates for CAP was 68–7000 per 100,000 and the 33 
incidence in hospitalized CAP cases of all causes was 16–3581 per 100,000. In general 34 
the incidence of CAP increased consistently with age. Available data indicated higher 35 
burdens of pneumococcal CAP caused in groups with more comorbidities. Most cases 36 
of pneumococcal CAP (30% to 78%) were caused by serotypes covered by PCV13 37 
vaccine; the incidence of PCV13-related pneumonia decreased after the introduction 38 
of childhood vaccination. 39 
Conclusions: We observed a high burden adult pneumococcal CAP in Europe despite 40 
use of the 23-valent pneumococcal polysaccharide vaccine, particularly in elderly 41 
patients with comorbidities. CAP surveillance presented wide variations across Europe. 42 
Pneumococcal CAP has to be monitored very carefully due to the possible effect of 43 
current vaccination strategies. 44 
45 
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Introduction 46 
Pneumonia is an important infectious disease associated with high morbidity, mortality 47 
and health costs worldwide (1,2). In 2015, data from the Global Burden of Disease 48 
study reported that lower respiratory tract infections, including pneumonia, were the 49 
third most common cause of death globally, exceeded only by ischaemic heart disease 50 
and cerebrovascular disease (3). Community-acquired pneumonia (CAP) remains the 51 
main cause of death from infectious disease globally, and is associated with 52 
considerable impact on morbidity and mortality, especially in older groups in which 53 
studies have linked the risk of death to increasing age (1,4,5). 54 
In general, and despite improved microbiological diagnostic technologies, the 55 
causative pathogen cannot be identified in approximately 50% of CAP cases (6,7). 56 
Nevertheless, the most frequently identified pathogen in CAP, regardless of setting, 57 
age or comorbidity, is still Streptococcus pneumoniae (pneumococcus) (4,6). This 58 
bacterium has more than 90 serotypes, of which some are associated with severe 59 
disease, high invasiveness, high case fatality and antimicrobial resistance. These 60 
characteristics have led to challenges in vaccine design, because their impact on 61 
preventing pneumococcal infection depends on the coverage of serotypes associated 62 
with invasive or resistant disease. 63 
Pneumonia, especially pneumococcal CAP, causes significant morbidity and economic 64 
burden in adults (8). However, its incidence is decreasingly reported in the United 65 
States, where recent published studies have indicated that 5%–15% of pneumonia 66 
cases were caused by pneumococcus(9). The major factors influencing this decrease 67 
are the universal introduction of the conjugate pneumococcal vaccination in children 68 
and adults (10) coupled with the decreased rate of smoking (11,12). By contrast, 69 
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pneumococcus remains the most frequent CAP pathogen in Europe, accounting for 70 
19% (range: 0%–67%) of cases in meta-analyses (6,8,13,14). The model of universal 71 
vaccination is important because adults, especially those with chronic diseases, are at 72 
increased risk of pneumococcal CAP and disproportionally affected by increased 73 
mortality and decreased quality of life (1,15). 74 
The introduction in 1983 of the 23-valent pneumococcal polysaccharide vaccine 75 
(PPSV23) led to an overall reduction in invasive pneumococcal disease (IPD) in most 76 
adult, excluding those with immunocompromised patients(16). Furthermore, the 77 
effectiveness of PPSV23 appears to decrease with age and time since vaccination, its 78 
use has no significant effect on S. pneumoniae carriage, and its efficacy against non-79 
invasive pneumococcal CAP is contentious (17–19). The 13-valent pneumococcal 80 
conjugate vaccine (PCV13); comprising serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 81 
19A, 19F and 23F, has been licensed in Europe since 2011 for adults aged ≥50 years, 82 
based on serologic noninferiority data (20). Recently, a proof-of-concept study in 83 
adults aged ≥65 years demonstrated that the PCV13 vaccine had efficacy values of 45% 84 
to 46% for confirmed vaccine-type CAP and non-bacteraemic non-invasive CAP, but a 85 
vaccine efficacy of 75% for vaccine-type IPD (not including meningitis) (21). In the 86 
United Kingdom, 8 years of vaccination with the 7-/13-valent pneumococcal conjugate 87 
vaccines (PCV7/PCV13) in children has seen a >50% overall reduction in the incidence 88 
of IPD for all ages (22). For adults, recommendations across the European Union now 89 
favour the use of PCV13 (with or without additional dose[s] of PPSV23) (23); PCV13 has 90 
recently been recommended for use alongside PPSV23 for pneumococcal disease 91 
prevention in US adults ≥65 years (24). 92 
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It is important to know the true incidence of pneumococcal CAP in Europe to inform 93 
effective management and prevention strategies. Our objective in this review was to 94 
summarise the available data regarding the incidence of pneumococcal CAP in 95 
European adults. We included cases in both non-hospitalised and hospitalised patients, 96 
as well as those caused by S. pneumoniae. A secondary objective was to assess the rate 97 
of pneumococcal CAP caused by serotypes covered by PCV13 vaccine. 98 
Methods 99 
The PubMed database was searched using the following search string: “Pneumonia” 100 
AND English AND ("Pneumococcal" OR "Community-acquired" OR "Streptococcus" OR 101 
"Community acquired" OR "CAP" OR "Hospitalised" OR "Hospitalised") AND (“Adults” 102 
OR “Adult” OR “Elderly” OR “Middle Aged” OR “Older”). Search results were restricted 103 
to clinical trials, letters, meta-analyses, observational studies and systematic reviews 104 
performed in European countries, as summarised in Table 1. We also include relevant 105 
citations that described studies conducted in Europe to obtain data about the 106 
incidence of pneumonia and/or coverage of PCV13 in individuals aged ≥18 years. 107 
Titles and abstracts were initially screened to identify relevant citations, which were 108 
then reviewed in full by two authors. We included all publications presenting data on 109 
pneumonia, regardless of definition, and reviewed the study setting, methodology, 110 
and characteristics of the study population. The definition of pneumococcal 111 
pneumonia varied between publications, 35 studies used the  World Health 112 
Organization International Classification of Diseases (ICD) codes, microbiological 113 
findings without radiographic diagnosis was used in 12 studies, and 3 used medical 114 
records only, other 3 studies did not specify the definition. Invasive pneumococcal 115 
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disease (IPD) was defined when isolation of Streptococcus pneumoniae from the blood 116 
or another normally sterile body site was reported. All authors confirmed the inclusion 117 
of the identified publications. Publications reporting data in only paediatric 118 
populations were excluded; as were those focusing solely on hospital- or healthcare-119 
acquired pneumonia (the incidence of such pneumonia is highly dependent on 120 
healthcare systems and medical practices). Relevant data from all identified sources 121 
were inserted into summary tables, including the study country, the study type, the 122 
microbiology and serotyping methodologies, the definition of pneumonia, the ages of 123 
participants and the year of study. 124 
The principal summary measure was the annual incidence of pneumonia per 100,000 125 
populations in each of the study countries. The following annual incidences were of 126 
interest: all-cause pneumonia, pneumococcal pneumonia, non-hospitalised 127 
pneumonia, hospitalised pneumonia and hospitalised pneumococcal pneumonia. 128 
Additional summary measures were 1) the percentage of cases of pneumococcal CAP 129 
caused by serotypes covered by PCV13 vaccine and 2) the pneumococcal vaccination 130 
uptake. 131 
132 
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Results 133 
Studies included  134 
We identified 2717 articles and included 73 publications covering 16 European 135 
countries after screening, (Figure 1) (5, 16, 20, 24–94). These publications are 136 
summarised in online supplementary Table S1. Of the included publications, 31 were 137 
prospective or surveillance (5,21,25,28,30,33,38,40,41,46,49,50,58,62,63,65–72,78–138 
83) and 42 were retrospective analyses (26,27,29,31,32,34–37,39,42–45,47,48,51–139 
57,59–61,64,73–77,84–93). 140 
National population-based epidemiologic surveillance data for pneumonia were 141 
available from Norway (54), Portugal (58) and Spain (59,75,77). As observed by 142 
Tichopad and colleagues (29), epidemiologic data in Central and Eastern Europe were 143 
predominantly collected from hospital settings, and there was a lack of data on 144 
outpatient CAP, with the authors instead using inpatient-to-outpatient ratios from a 145 
retrospective chart review to estimate outpatient incidence in the Czech Republic, 146 
Hungary, Poland and Slovakia. Three studies specified the number of patients with 147 
prior pneumonia before the index case(31,85,90). 148 
The countries with the most data sources were Spain (23 studies plus an additional 149 
study combining Italian and Spanish data) (5,25,28,49,59–78) and the United Kingdom 150 
(14 studies)(80–88) followed by Italy (7 plus the additional study combining Italian and 151 
Spanish data) (42–49), the Netherlands (6 studies)(21,27,50–53), Germany (26,37–40) 152 
and France (34–36,94,95) (5 studies each), Denmark (30–32) and Poland (29,55,56) (3 153 
studies each), and Portugal (2 studies)(57,58). Single studies were identified reporting 154 
data from the Czech Republic (29), Finland (33), Greece (41), Hungary (29), Norway 155 
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(54), Slovakia (29), and Sweden (79). Data from other European countries were not 156 
found. 157 
The definition of pneumonia varied between publications, with some authors using a 158 
combination of methods. Specifically, 25 of the 73 publications used radiographic 159 
diagnosis in all or most cases (5,20,27,29,30,32,35,36,40,45,48,49,60,64,66,67,70,71, 160 
77,79–82,93,94), 35 used the World Health Organization International Classification of 161 
Diseases (ICD) codes (5,25–27,29,31,32,34,37,39,42,43,45,47,48,53–162 
57,59,60,63,69,70,75–77,79,86,89–93), 12 used clinical signs and/or microbiological 163 
findings without radiographic diagnosis (35,40,51,52,62,64,66,73,74,81–83), 3 used 164 
medical records only (84,87,88), and 3 did not specify the definition (29,58,85). 165 
Burden of Disease 166 
Data on the incidence of pneumonia are presented in online supplementary Table S2. 167 
The incidence of all-cause pneumonia in Europe was 68–7000 per 100,000 population, 168 
but this varied by country, age group, study and time period (Table 2) (5,25,28,29,35–169 
37,39–41,46,49,51,53,55,64,69,72,84,88,89,91,93). The lowest incidence of all-cause 170 
pneumonia was reported in Spain between 1999 and 2001 in patients aged 15–44 171 
years (72), and the highest incidence was reported in France between 2011 and 2012 172 
in patients aged >65 years (35). 173 
Spain reported the highest incidence rates for pneumococcal CAP (166 per 100,000) 174 
(25) and IPD (or invasive pneumococcal CAP; 60 per 100,000)(69) in patients aged ≥60 175 
and ≥65 years, respectively. 176 
Data from national population based epidemiological surveillance for pneumonia were 177 
reported by Spain, Portugal and Norway. The Norway surveillance (54) reported the 178 
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incidence of pneumonia of two years (2208- 2009). They observed a relative stable 179 
incidence of all cause pneumonia, in 2008 the incidence was 5.28 cases per 100,000 180 
and in 2009 were 5.35 cases per 100,000. However, they observed a decrease in the 181 
incidence of pneumococcal pneumonia from 13.66 cases per 100, 000 in 2008 to 10.52 182 
cases per 100,000 in 2009. Data from Portugal surveillance (57) in the a study period 183 
between 2000 to 2009, reported that the average annual rate of hospital admissions 184 
for adults with CAP was 3.61 per 1000 total population, this rate increased in those 185 
aged ≥65 years to 13.4  per 1000 . The authors reported that between 2000-2004 and 186 
2005-2009 the average annual rate of hospital admission for CAP per 1000 population 187 
increased by 28.2%.  188 
Data from Spain surveillance was reported in 3 studies: The first study (77) include 189 
data from the year’s 1995 y 1996. The incidence of hospitalizations for pneumonia was 190 
162 per 100,000 population in the year 1995 and 189 cases per 100,000 population in 191 
1996. Adults ≥ 65 years accounted for 49.5% of cases. The second study (75) covered 192 
the period 1995 to 1998. The annual incidence of pneumonia was 177 cases per 193 
100,000 population. The incidence was higher in children <5 years of age and in adults 194 
≥ 65 years compared with other age groups. The third study (59) covered the period 195 
2003 to 2007. The annual hospitalisation rate for all cause pneumonia was 6.27 cases 196 
per 1000 and the incidence of pneumococcal pneumonia was 1.09 cases per 1000.  197 
The highest incidence of non-hospitalised CAP (3575 per 100,000) was reported in 198 
Hungary in patients aged ≥65 years (29). The incidence of hospitalisation due to CAP 199 
was 16 to 3581 per 100,000 population and varied by country, age group, study, and 200 
time period (Table 2) (26,29,31,33,34,42,44,49,53,54,56,57,59,67,70,75,79,80,92,93). 201 
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The lowest incidence of hospitalised CAP was reported in the United Kingdom between 202 
2008 and 2010 in patients aged 16 to 24 years (80), and the highest incidence was 203 
reported in Germany in 2005 to 2006 in patients aged ≥90 years (26) (Table 2). 204 
For hospitalised pneumococcal CAP, the highest incidence (421 per 100,000 205 
population) was reported in Spain in patients aged ≥85 years (96) (Table 2). Data on 206 
hospitalised IPD or invasive pneumococcal CAP were only available from Spain, 207 
however, with the incidence ranging from 7 per 100,000 population in patients of all 208 
ages (74) to 45 per 100,000 population in patients aged >64 years (70) (Table 2). 209 
The incidence rates for all-cause pneumonia, pneumococcal CAP, non-hospitalised 210 
CAP, hospitalised CAP and hospitalised pneumococcal CAP all increased with age 211 
(Supplemental Table S2) (5,26–29,31,34–36,39,40,44,46,51,53–57,60,64,67,70–72,74–212 
77,80,88,89,91–93,96). 213 
We observed temporal trends between countries. An increase in the incidence of 214 
pneumonia over time was observed in the Netherlands (53) and there was a decrease 215 
over time in Poland (55). An increase incidence in hospitalised pneumococcal CAP was 216 
reported in Spain over time (73). Similarly, there were increases in the incidence of IPD 217 
over time in France(36) and the United Kingdom(91), though there was a decrease in 218 
pneumococcal CAP in the Netherlands(51). Increases in the incidence rates of 219 
hospitalised CAP were also reported over time in Denmark (31), Germany (26), the 220 
Netherlands (53), Portugal (57), and the United Kingdom (91,92). However, there was 221 
only minimal or variable change in France (34) and Italy (43,47,48), and a minimal 222 
change or decrease in Norway that was dependent on age (54). There was an increase 223 
in hospitalised pneumococcal CAP in Spain (67), a minimal change in France (34), and a 224 
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decrease in Norway (54) and the United Kingdom (83). 225 
Associations between the incidence of pneumonia and comorbidities were reported in 226 
11 publications, including solid organ and allogeneic haematopoietic stem cell 227 
transplantation (49,68), systemic lupus erythematosus (52), chronic medical conditions 228 
that that require pneumococcal vaccination (39), HIV infection (73,94,95), pernicious 229 
anaemia (85), diabetes (86,87), and chronic obstructive pulmonary disease (90) (Online 230 
supplementary Table S3). Patients with chronic diseases presented the highest 231 
pneumonia incidence rates, with the highest all-cause incidence reported for 232 
allogeneic haematopoietic stem cell transplantation recipients in Spain (aged >14 233 
years, 52,200 per 100,000) (68) and the highest hospitalised incidence reported in 234 
older male patients with type 2 diabetes in the United Kingdom (aged ≥65 years, 1070 235 
per 100,000) (87). 236 
Pneumococcal Serotypes Covered by the PCV13 Vaccine 237 
Data on pneumococcal infection caused by serotypes covered by PCV13 vaccine in 238 
European countries are show in Online Supplementary Table S4. Twenty-three 239 
publications reported data on pneumococcal serotypes and outcomes 240 
(21,30,33,36,38,40,50,51,54,58,61,62,65–67,69,70,73,80–83,91), but the method for 241 
serotyping varied between studies, including urinary antigen testing (3 studies) 242 
(21,38,50), agglutination testing (7 studies) (30,36,61,80–83), the Quellung reaction (7 243 
studies) (30,40,50,51,65,67,69), polymerase chain reaction (PCR; 3 studies)(65,66,70), 244 
and the capsular reaction test (1 study) (58) (Online Supplementary Table S1). 245 
Studies from Finland (33) and the United Kingdom(83) reported the highest 246 
percentages of CAP caused by pneumococcal serotypes covered by the PCV13 vaccine 247 
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(78% per study). In a Spanish study of patients with cancer who developed 248 
pneumococcal bacteraemia, pneumonia was the most frequent source in 84% of cases, 249 
and 54% of cases were caused by serotypes covered by the PCV13 vaccine (65). 250 
Researchers from the United Kingdom investigated the impact of PCV13 on 251 
pneumococcal serotypes implicated in a predominantly non-bacteraemic cohort of 252 
pneumococcal CAP adults. In that study, it was reported that the incidence of 253 
pneumonia caused by serotypes included in PCV13 vaccine declined from 10.6 to 6.3 254 
per 100,000 population over the 5-year period after the PCV13 was introduced as part 255 
of the childhood vaccination schedule, suggesting that herd protection from infant 256 
PCV13 affected the incidence of adult non-bacteraemic pneumococcal CAP (83). 257 
Data on the efficacy of PCV13 vaccine was specifically reported in one study. A 258 
randomised, double-blind, placebo-controlled trial (the Community-Acquired 259 
Pneumonia Immunization Trial in Adults [CAPiTA]) was conducted in the Netherlands. 260 
This involved 84,496 adults aged 65 years and over during the period from 2008 to 261 
2013, reported an efficacy of 45.5% (95.2% confidence interval [CI], 21.8–62.5; p < 262 
0.001) for PCV13 against all vaccine-type pneumococcal CAP, a 45% efficacy (95.2% CI, 263 
14.2–65.3; p < 0.001) against vaccine-type non-bacteraemic pneumococcal CAP and a 264 
75% efficacy (95.2% CI, 41.4–90.8; p < 0.001) against vaccine-type IPD among adults 265 
aged ≥65 years (21). 266 
Data on vaccination uptake are shown in online supplementary Table S5. However, 267 
detailed stratification for the incidence of pneumonia relative to PCV13 uptake in 268 
these studies is beyond the scope of this review. Of note, based on the limited data 269 
identified in our review, there has been large variation in the reported uptake of the 270 
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pneumococcal vaccination (45,49,60,79–83). 271 
Discussion 272 
This review showed a notable burden of pneumococcal CAP in European adults, 273 
particularly among the elderly. Data on comorbidities were limited, but suggested a 274 
high incidence of pneumonia in patients with chronic diseases. Older patients are 275 
especially vulnerable to pneumonia because of both age-related changes in the 276 
immune system and a greater prevalence of chronic diseases. For this reason, it is 277 
difficult to determine the precise cause of increased risk in these patients. However, 278 
the disproportionate burden of pneumococcal disease in older patients should remind 279 
us that the incidence of pneumonia and risk of death remain linked to increasing age 280 
(4,5,28,34). These data support the importance of adequate prevention against 281 
pneumococcal CAP, especially in the elderly population. 282 
The incidence of adult all-cause CAP decreased in the United Kingdom (where infant 283 
PCV uptake is >90%) from 91 to 65 cases per 100,000 between 2008 and 2012 (83) 284 
after the introduction of the paediatric PCV13 vaccine. However, despite this, there 285 
remains a substantial burden of pneumococcal CAP caused by serotypes covered by 286 
PCV13 vaccine (i.e., 30%–78%) (42,43,45), even after the introduction of the PCV to 287 
infant vaccination schedules in 2005 (42,97). The level of paediatric vaccination uptake 288 
required to produce herd immunity in other age groups is currently unknown, 289 
although data from the UK and US indicate substantial reductions in IPD associated 290 
with universal childhood PCV vaccination (22,98). A study from US that evaluated the 291 
direct and indirect effects of PCV13 reported that the introduction of PCV13 292 
substantially reduced the numbers of patients with IPD, non-invasive CAP and all-cause 293 
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CAP in both vaccinated children and unvaccinated adults. Nevertheless, because the 294 
study considered only the first 2 years after the introduction of PCV13, a period in 295 
which approximately 50% of children in the US received the vaccine, the true effect of 296 
PCV13 on pneumococcal diseases was not fully measured (99). Notably, there are a 297 
lack of data on the overall incidence and prevalence of pneumococcal CAP caused by 298 
serotypes covered by PCV13, including the incidence in patients with comorbidities. 299 
Our review identified variability in the reporting of pneumococcal incidence across 300 
European countries, including a lack of studies from several countries, with differences 301 
in the reported methodologies used and outcomes measured. The resulting absence of 302 
comprehensive and reliable data on pneumococcal CAP is of concern. For instance, the 303 
lack of such data may lead to decisions regarding vaccination programmes being 304 
reliant on IPD data, thereby underestimating the true burden of pneumococcal 305 
disease. In the United Kingdom, for example, data from 2013 to 2014 showed that the 306 
incidence of IPD caused by PCV13 serotypes was 4.3 per 100,000 in patients aged ≥65 307 
years (22), and that in the same period, the incidence rates for hospitalised adults 308 
were 20.6 per 100,000 for those with pneumococcal CAP (including non- invasive 309 
disease) and 8.6 per 100,000 for those with pneumococcal CAP caused by PCV13 310 
serotypes (100). Underestimation of non-bacteraemic pneumococcal CAP may also 311 
result from a lack of appropriate diagnostic tools. If 10% to 20% of patients with 312 
pneumococcal CAP have bacteraemia, preventing 5% of all cases may have more of an 313 
impact than preventing 75% of patients with IPD. 314 
In this review, the reported incidence of pneumonia varied widely between countries 315 
and across regions within countries, with socioeconomic effects likely to be 316 
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contributory (88). Only Norway (54) Portugal (57) and Spain (59, 75,77) reported data 317 
from population based studies. The differences in the incidence and CAP and PCAP 318 
between these countries are difficult to interpret and might be due to differences in 319 
the populations studied.  In addition some factors that contribute to these  differences  320 
include the impact of lifestyle factors such as smoking, high alcohol intake, being 321 
underweight, living in a large household or having regular contact with children (101). 322 
Also, the national immunization practices that in some regions widespread the use of 323 
pneumococcal polysaccharide vaccine in adults and the use of conjugate 324 
pneumococcal vaccine in children could influence  the reported incidence of 325 
pneumococcal CAP(102). Similarly, the use of influenza vaccination in adults could 326 
influence variations in the incidence of pneumonia(103). Also, much of the variation is 327 
likely to have been due to differences in medical systems and practices, rather than 328 
differences in underlying epidemiology.  Indeed, research highlights the difficulties in 329 
estimating the incidence of pneumonia in the community. In Germany, for example, 330 
four estimation approaches yielded different annual incidence rates for pneumonia in 331 
adults, ranging from 370 to 1230 per 100,000 inhabitants in an urban area(37). In that 332 
study, the incidence based on cases reported in general practice was thought to give 333 
an underestimate because of underreporting and inaccurate estimation of the 334 
population size (lack of patient registration in medical practices). In addition, the 335 
incidence of hospitalised CAP depends on the structure of the primary and secondary 336 
healthcare systems (60). Countries with uniformly organised healthcare systems (e.g., 337 
Denmark) are able to collect data for hospitalisation (31), which facilitates the 338 
development of population-based designs. Furthermore, although every attempt was 339 
made to exclude studies from our review that included patients with hospital-acquired 340 
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pneumonia, we cannot exclude the possibility that at least some of the cohorts 341 
included patients who did not have CAP. 342 
Classification schemes varied between the publications included in our review. Many 343 
studies used ICD-9 or -10 codes, which offer different coding for pneumococcal 344 
pneumonia. ICD-9 codes for pneumococcal pneumonia have been associated with low 345 
sensitivity (104), and consequently, the hospitalised pneumonia incidence may have 346 
been underestimated. However, the ICD-10 coding for pneumonia does not necessarily 347 
imply microbiological confirmation (54). Accuracy depends on initial coding, and 348 
studies have demonstrated the potential for inaccuracies in administrative data 349 
(105,106). 350 
A wide range of microbiological methods were used to diagnose pneumococcal CAP 351 
and identify serotypes in the studies in this review. These methods included standard 352 
culture and PCR-based methods for bacterial identification, as well as agglutination 353 
techniques and the Quellung reaction for serotyping. More recently, urinary antigen 354 
tests have become available, which facilitate identification of pneumococcal infections 355 
and may increase the accuracy in determining the burden of pneumococcal CAP. 356 
In conclusion, this review of the incidence of pneumococcal CAP in European adults 357 
highlights the considerable variation in the types of studies and methodologies used 358 
between and within European countries, including the lack of surveillance 359 
programmes. Nevertheless, the available data demonstrate the significant burden of 360 
pneumococcal CAP, especially in the elderly. Given that pneumococcal CAP in the 361 
elderly increases the risk of mortality three-fold compared with non-pneumococcal 362 
CAP, underestimating the incidence of pneumococcal disease could have a major 363 
impact on healthcare outcomes. Pneumococcal CAP has to be monitored very carefully 364 
due to the possible effect of current vaccination strategies. 365 
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Table 1. Search Terms and Limits 730 
 731 
Search terms: “Pneumonia” AND ("Pneumococcal" OR "Community-acquired" OR 732 
"Streptococcus" OR "Community acquired" OR "CAP" OR "Hospitalized" OR 733 
"Hospitalised") AND (“Adults” OR “Adult” OR “Elderly” OR “Middle Aged” OR 734 
“Older”) AND (“Albania” OR “Andorra” OR “Armenia” OR “Austria” OR “Azerbaijan” 735 
OR “Belarus” OR “Belgium” OR “Bosnia and Herzegovina” OR “Bulgaria” OR 736 
“Croatia” OR “Cyprus” OR “Czech Republic” OR “Denmark” OR “England” OR 737 
“Estonia” OR “Europe” OR “European Union” OR “Finland” OR “France” OR 738 
“Georgia” OR “Germany” OR “Great Britain” OR “Greece” OR “Hungary” OR 739 
“Iceland” OR “Ireland” OR “Italy” OR “Kazakhstan” OR “Kosovo” OR “Latvia” OR 740 
“Liechtenstein” OR “Lithuania” OR “Luxembourg” OR “Macedonia” OR “Malta” OR 741 
“Moldova” OR “Monaco” OR “Montenegro” OR “Netherlands” OR “Northern 742 
Ireland” OR “Norway” OR “Poland” OR “Portugal” OR “Romania” OR “Russia” OR 743 
“San Marino” OR “Scotland” OR “Serbia” OR “Slovakia” OR “Slovenia” OR “Spain” 744 
OR “Sweden” OR “Switzerland” OR “Turkey” OR “Ukraine” OR “United Kingdom” OR 745 
“UK” OR “Vatican City” OR “Wales”) 746 
 747 
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Search limits: Humans; Published from 1 January 2000 to 31 October 2016 748 
 749 
 750 
751 
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Table 2. Incidence of pneumonia in European countries per 100,000 per year 
Country Non-hospitalized Hospitalized Pneumococcal CAP All cause pneumonia 
 
CZ: Czech Republic 
 
≥ 50 years: 300 
≥65 years: 370 
≥ 50 years: 472 
≥65 years: 833 
- - 
DK: Denmark 
 
- 15-39 years: 2800 
≥80 years: 2003 
- ≥65 years: 1270 
DE: Germany 
 
- ≥60 years: 765 ≥65 years: 16.2 (IPD) 18-49 years:441 
50-59 years: 684 
≥60 years:1439 
FR: France 
 
Adults: 400  - 
 
Adults: 7.4 (IPD) 
Adults: 17.41  
- 
 
FI: Finland 
 
- -  
≥65 years: 95 
 
≥65 years : 550 
GR: Greece 
 
- - - ≥ 50 years: 274 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
30 
 
HU: Hungary 
 
≥ 50 years: 3.346 
≥65 years: 3.575 
 
≥ 50 years: 832 
≥65 years: 1.414 
- - 
IT: Italy 
 
- - 13.4 Adults: 320.1 
 
NL: Netherlands 
Adults: 109 Adults: 176 ≥65 years: 47.11 (2004-2006) 
≥65 years: 36.66 (2008-2012) 
Adults: 295 
≥65 years: 881 
NO: Norway 
 
- Adults: 531 Adults: 12.09 - 
SK: Slovakia 
 
≥ 50 years: 587 
≥65 years: 771 
≥ 50 years: 518 
≥65 years: 938 
 
 
- - 
PL: Poland 
 
≥ 50 years: 316 
≥65 years: 442 
≥ 50 years: 366 
≥65 years: 706 
 
- - 
PT: Portugal - Adults: 361 - - 
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≥65 years: 1340 
 
SE: Sweden - 65-79 years: 107.6 
≥80 years: 510.6 
- - 
ES: Spain 
 
2002-2005 
Adults: 350 
 
1995- 1996 
≥65 years: 523 
 
1995-1998 
≥80 years: 998 
1999- 2001 
Adults: 123 
≥75 years: 526 
2002-2005 
Adults: 1050 
2003 – 2007 
Adults: 627 
 
1999- 2001 
Adults: 20.7 
≥75 years: 10.0 
2009 
Adults >64 years: 44.7 (IPD) 
2003 – 2007 
Adults: 109 
 
 
2002-2005 
Adults:140 
65-74 years: 99 
≥85 years:294 
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GB: United Kingdom 
 
- Adults: 79.9 Adults: 23.4 
Adults IPD: 14.1 
16-44 years: 12.1 
≥85 years: 274.1 
 
Adults: 799 
Note: values ate the mean reported in the identified publications for each respective country. Does not include patients with comorbidities or the 
combined study from Italy and Spain 
48
, and values are irrespective of sex. Refer to Supplemental Table S1 and Suplemental Table S2 for additional 
details regarding each publication. IPD: invasive pneumococcal disease. 
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Highlights 
 
• The data available demonstrate the significant burden of pneumococcal CAP in 
European adults, especially in the elderly. 
• Pneumococcal CAP in the elderly increases the risk of mortality three-fold 
compared with non-pneumococcal CAP. 
• Pneumococcal CAP has to be monitored very carefully, due to the possible 
effects of current vaccination strategies. 
